Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to age-related macular degeneration

Retina

Volumn 32, Issue 2, 2012, Pages 293-298

  Katz, Gabriel ^a   Giavedoni, Louis ^a   Muni, Rajeev ^a   Evans, Teodoro ^a   Pezda, Matthew ^a   Wong, David ^a   Moffat, Ashley ^a   Altomare, Filiberto ^a   Boyd, Shelley ^a   Berger, Alan ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

1 year; AMD; OCT; ranibizumab; variable dosing; visual acuity

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84856600668     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821e20b0     Document Type: Article

References (17)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
3. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143: 566-583.
4. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
5. Meyer CH, Eter N, Holz FG, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age related macular degeneration. Interim results from the SUSTAIN trial. Invest Ophthalmol Vis Sci 2008;49:E-abstract 273.
6. Holz FG. SOE: flexibly dosed ranibizumab in patients with neovascular AND: twelve months interim results of the SUSTAIN Trial. Abstract PA078 presented at the AAO/SOE Joint Annual Meeting, 8-11 November 2008, Atlanta, GA.
7. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148: 409-413.
8. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010;94:292-296.
9. Engelbert M, Zweifel SA, Freund KB. ''Treat and extend'' dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29:1424-1431.
10. Kang S, Roh YJ. One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol 2009;53:389-395.
11. Ernst BJ, Barkmeier AJ, Akduman L. Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Int Ophthalmol 2010;30:267-270.
12. Michalova K, Wickremasinghe SS, Tan TH, et al. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye (Lond) 2009; 23:1633-1640.
13. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-290. (Pubitemid 38366348)
14. Kiernan DF, Hariprasad SM, Chin EK, et al. Prospective comparison of cirrus and Stratus optical coherence tomography for quantifying retinal thickness. Am J Ophthalmol 2009;147: 267-275.
15. Grover S, Murthy RK, Brar VS, et al. Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci 2010;51: 2644-2647.
16. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
17. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizu-mab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-1747.